Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07583823 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Elevated Rate Pacing of Cardiac Amyloidosis

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 31 days later Oct 10, 2026 → Nov 10, 2026
See other at-risk trials from University of Minnesota

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion pushed from Oct 10, 2026 to Nov 10, 2026
    • Eligibility criteria expanded, about 9 words
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study aims to better quantify the improvements in heart failure symptoms and exercise tolerance before and after the heart rate elevation in a cohort of 10 cardiac amyloidosis patients with preexisting pacemakers.
Trial Details
NCT Number NCT07583823
Lead Sponsor University of Minnesota
Conditions
(from sponsor)		 Cardiac Amyloidosis, Pacemaker
Related terms Amyloid Neuropathies, Familial
Enrollment 10 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov